We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Collaboration Designed to Accelerate Development of Personalized Cancer Therapeutics

By LabMedica International staff writers
Posted on 27 Mar 2016
Print article
Two European biotechnology companies are to collaborate on the development of cell and gene based treatment strategies in order to optimize the manufacture and delivery of personalized cancer therapeutics.

GlaxoSmithKline (Brentford, United Kingdom) and Miltenyi Biotec (Bergisch Gladbach, Germany) recently announced an agreement to collaborate in a program to merge GlaxoSmithKline’s expertise in developing cell and gene therapy based treatments with Miltenyi Biotec’s cell processing and counting technologies.

Through the collaboration, Miltenyi Biotec will introduce greater automation and high-tech processing technology into GlaxoSmithKline’s current cell and gene therapy research and developing manufacturing capabilities. The goal is to use this increased automation to industrialize cell and gene therapies, overcoming the manufacturing constraints associated with current processes. This should reduce costs and hasten development efforts.

The collaboration will also unite the methodology and expertise of both companies to advance the discovery of new CAR (chimeric antigen-receptor) T-cell based therapeutics, in which cells are engineered to target and destroy cancer cells by strengthening a patient’s natural T-cell response.

Patrick Vallance, president of pharmaceuticals research and development at GlaxoSmithKline, said, “Cell based gene therapies are living treatments, unique to individual patients and complex to manufacture. We see tremendous potential for the cell and gene therapy platform we are building within GSK, however the complexity of current manufacturing processes limits their use to local treatment of small patient populations. Working with Miltenyi Biotec, our vision is to transform current technology so that we can expand the possibilities for cell and gene therapy treatment to wider patient populations with broader geographical reach.”

Stefan Miltenyi, CEO of Miltenyi Biotec, said, “For more than 20 years we have been developing and providing cell therapy solutions to patients worldwide. Working together with the global experts at GlaxoSmithKline, we will accelerate innovation to broaden patient access to future personalized cell and gene therapy.”

Related Links:

GlaxoSmithKline
Miltenyi Biotec


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.